Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter
Daxor (Nasdaq: DXR), a leader in blood volume measurement technology, reported significant growth in its mid-year update for 2024. Key highlights include:
1. Net Asset Value (NAV) increased to $6.75 per share from $6.33 last year.
2. Unaudited revenue for the first half of 2024 more than doubled compared to 2023.
3. Added 14 new accounts, surpassing the 12 added in 2023.
4. Reduced net cash investment to $1.297 million from $2.445 million in H1 2023.
5. Secured $2.45 million in government contracts for technology development.
6. Acquired Volumex®, Megatope®, and Glofil® to improve margins and expand product offerings.
7. Expecting operational positive cash flow by Q4 2024.
Daxor (Nasdaq: DXR), leader nella tecnologia di misurazione del volume sanguigno, ha riportato una crescita significativa nel suo aggiornamento di metà anno per il 2024. I punti salienti includono:
1. Il Valore Netto degli Attivi (NAV) è aumentato a 6,75 dollari per azione rispetto a 6,33 dollari dell'anno scorso.
2. I ricavi non verificati per il primo semestre del 2024 sono più che raddoppiati rispetto al 2023.
3. Aggiunti 14 nuovi conti, superando i 12 aggiunti nel 2023.
4. Investimento netto in contante ridotto a 1,297 milioni di dollari, rispetto ai 2,445 milioni di dollari nel primo semestre del 2023.
5. Ottenuti 2,45 milioni di dollari in contratti governativi per lo sviluppo della tecnologia.
6. Acquisite Volumex®, Megatope® e Glofil® per migliorare i margini e ampliare l'offerta di prodotti.
7. Ci si aspetta un flusso di cassa operativo positivo entro il quarto trimestre del 2024.
Daxor (Nasdaq: DXR), líder en tecnología de medición del volumen sanguíneo, reportó un crecimiento significativo en su actualización de mitad de año para 2024. Los aspectos destacados incluyen:
1. El Valor Neto de los Activos (NAV) aumentó a 6,75 dólares por acción desde 6,33 dólares el año pasado.
2. Los ingresos no auditados para la primera mitad de 2024 más que se duplicaron en comparación con 2023.
3. Se añadieron 14 nuevas cuentas, superando las 12 añadidas en 2023.
4. Inversión neta en efectivo reducida a 1,297 millones de dólares desde 2,445 millones de dólares en la primera mitad de 2023.
5. Asegurados 2,45 millones de dólares en contratos gubernamentales para el desarrollo tecnológico.
6. Adquiridos Volumex®, Megatope® y Glofil® para mejorar los márgenes y expandir la oferta de productos.
7. Se espera un flujo de efectivo operativo positivo para el cuarto trimestre de 2024.
Daxor (Nasdaq: DXR), 혈액량 측정 기술의 선두주자인 Daxor는 2024년 중반 업데이트에서 significant 성장률을 보고했습니다. 주요 하이라이트는 다음과 같습니다:
1. 순자산 가치(NAV)가 지난해 6.33달러에서 6.75달러로 증가했습니다.
2. 2024년 상반기 비공식 매출은 2023년에 비해 두 배 이상 증가했습니다.
3. 14개 신규 계정 추가, 2023년의 12개를 초과했습니다.
4. 2023년 상반기 2.445백만 달러에서 1.297백만 달러로 순 현금 투자를 줄였습니다.
5. 기술 개발을 위한 245만 달러의 정부 계약을 확보했습니다.
6. 마진 개선과 제품 라인 확장을 위해 Volumex®, Megatope® 및 Glofil®을 인수했습니다.
7. 2024년 4분기까지 운영 긍정적 현금 흐름이 기대됩니다.
Daxor (Nasdaq: DXR), leader dans la technologie de mesure du volume sanguin, a rapporté une croissance significative dans sa mise à jour semestrielle pour 2024. Les points saillants comprennent :
1. La Valeur Nette des Actifs (NAV) a augmenté à 6,75 dollars par action, contre 6,33 dollars l'année dernière.
2. Les revenus non audités pour le premier semestre 2024 ont plus que doublé par rapport à 2023.
3. Ajout de 14 nouveaux comptes, dépassant les 12 ajoutés en 2023.
4. Réduction de l'investissement net en espèces à 1,297 million de dollars contre 2,445 millions de dollars au S1 2023.
5. Obtention de 2,45 millions de dollars en contrats gouvernementaux pour le développement technologique.
6. Acquisition de Volumex®, Megatope® et Glofil® pour améliorer les marges et élargir l'offre de produits.
7. Attente d'un flux de trésorerie opérationnel positif d'ici le T4 2024.
Daxor (Nasdaq: DXR), führend in der Technologie zur Messung des Blutvolumens, berichtete über ein erhebliches Wachstum in seinem Halbjahres-Update für 2024. Die wichtigsten Highlights sind:
1. Der Nettovermögenswert (NAV) stieg auf 6,75 Dollar pro Aktie von 6,33 Dollar im letzten Jahr.
2. Die unverifizierten Einnahmen für das erste Halbjahr 2024 verdoppelten sich mehr als im Vergleich zu 2023.
3. 14 neue Konten hinzugefügt, die 12 hinzugefügten Konten im Jahr 2023 übertreffen.
4. Investition in Bar wurde auf 1,297 Millionen Dollar von 2,445 Millionen Dollar im H1 2023 reduziert.
5. 2,45 Millionen Dollar in Regierungsverträgen für die Technologieentwicklung gesichert.
6. Volumex®, Megatope® und Glofil® erworben, um die Margen zu verbessern und das Produktangebot zu erweitern.
7. Erwarten positiven operativen Cashflow bis Q4 2024.
- Revenue more than doubled in H1 2024 compared to H1 2023
- Net Asset Value (NAV) increased to $6.75 per share from $6.33 last year
- Added 14 new accounts in 2024, surpassing the 12 added in 2023
- Reduced net cash investment to $1.297 million from $2.445 million in H1 2023
- Secured $2.45 million in government contracts for technology development
- Acquired Volumex®, Megatope®, and Glofil® to improve margins and expand product offerings
- Expecting operational positive cash flow by Q4 2024
- Operating Division still not profitable, with a net cash investment of $1.297 million in H1 2024
Insights
Daxor 's mid-year update reveals impressive financial growth and strategic advancements. The doubling of revenue in H1 2024 compared to H1 2023 is a strong indicator of market traction. The increase in
The reduction in net cash investment to
The strategic acquisition of Volumex®, Megatope® and Glofil® should enhance margins and diversify revenue streams. However, investors should monitor the integration process and its impact on financials in the coming quarters.
Daxor's Blood Volume Analysis (BVA) technology is gaining significant traction in the medical community. The expansion to new facilities, particularly in cardiac care, indicates growing clinical acceptance. The launch at the largest integrated network in the Mid-South is a notable achievement that could lead to further adoptions.
The development of a next-generation point-of-care analyzer, pending FDA approval, could be a game-changer. With 3x faster results and bedside capabilities, it has the potential to dramatically increase utilization and market penetration in both inpatient and outpatient settings.
Recent studies demonstrating BVA-100™'s benefits in ambulatory heart failure patients strengthen its scientific foundation. This could lead to expanded indications and broader adoption, potentially opening new revenue streams for Daxor.
The securing of
These contracts not only provide immediate revenue but also validate the technology's potential in military and civilian applications. The 24-month revenue flow from these contracts offers a stable income stream and could lead to larger, long-term government partnerships.
Investors should view these contracts as both a revenue source and a potential catalyst for future growth in government and related civilian markets.
Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.
Dear Valued Shareholders,
I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting Daxor Corporation's remarkable progress and financial performance. Our commitment to innovation in blood volume analysis (BVA) technology continues to drive growth and create value for our stakeholders.
Financial Highlights: I am thrilled to report that our financial position has strengthened significantly. Our Net Asset Value (NAV) has increased to
Our Operating Division is making significant strides towards profitability. The net cash investment for the first half of 2024 was
Looking ahead, we remain confident in achieving operational positive cash flow by the end of Q4 2024, driven by our commercial growth and newly awarded government contracts.
Expansion and Recognition: Our BVA technology continues to gain traction nationwide. Notable achievements include:
- Launch of our BVA program at the largest integrated network in the Mid-South.
- Expansion to three new facilities for cardiac care, reflecting growing momentum for our technology on the East Coast.
- New hospital account at a leading Chicago hospital for heart failure and general cardiology care.
Government Contracts: We have secured additional significant government contracts validating the importance of BVA. The work on these contracts have begun as of August 1st, and revenues from them will flow in the next 24-months:
$1.9 million contract from the U.S. Air Force for developing our next-generation tracer system.$550,000 contract from the U.S. Defense Health Agency for enhancing our point-of-care blood volume analyzer.
These contracts not only provide funding, but also underscore the potential applications of our technology in both civilian and military settings.
Product Development: We continue to work closely with the FDA towards final approval of our next-generation point-of-care blood volume analyzer along the 510(k) pathway. This new system is three times faster than our existing model and capable of completing the diagnostic test entirely at the bedside. We anticipate this advancement will significantly increase utilization at existing accounts and accelerate the opening of new accounts across the country for both inpatient and outpatient use.
Strategic Acquisition: In a move to enhance our product offerings and improve margins, we acquired Volumex®, Megatope®, and Glofil® from our existing supplier in March. This acquisition is expected to significantly improve our margins and drive increasing revenue through the introduction of new products to our growing customer base.
Research and Development: Recent studies have demonstrated the clinical benefits of our BVA-100™ diagnostic in ambulatory heart failure patients for measuring congestion, further solidifying the scientific foundation of our technology.
Leadership Enhancement: We welcomed Dr. John L. Jefferies as our new Chief Medical Officer in April, bringing valuable expertise to our leadership team.
In conclusion, the first half of 2024 has been a period of substantial growth and achievement for Daxor Corporation. Our financial performance, technological advancements, and strategic moves have positioned us strongly for continued success. We remain committed to our mission of and look forward to building on this momentum in the second half of the year and beyond.
Thank you for your continued support and trust in Daxor Corporation.
Sincerely,
Michael Feldschuh
CEO & President, Daxor Corporation
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What was Daxor 's (DXR) revenue growth in the first half of 2024?
How many new accounts did Daxor (DXR) add in 2024 so far?
What government contracts did Daxor (DXR) secure in 2024?
When does Daxor (DXR) expect to achieve operational positive cash flow?
What strategic acquisition did Daxor (DXR) make in 2024?
